# Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

> **NCT07030621** · PHASE3 · NOT_YET_RECRUITING · sponsor: **RenJi Hospital** · enrollment: 436 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Semaglutide 0.5 mg
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT07030621
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2027-07-31
- **Final completion:** 2028-01-31
- **Target enrollment:** 436 (ESTIMATED)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07030621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07030621, "Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT07030621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*